You are here:

fondaparinux (Arixtra)


In the absence of a submission from the holder of the marketing authorisation.

fondaparinux (Arixtra) is not recommended for use within NHS Scotland for the treatment of acute deep vein thrombosis (DVT) and the treatment of acute pulmonary embolism (PE).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Drug Details

Drug Name: fondaparinux (Arixtra)
SMC Drug ID: 262/06
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Acute deep vein thrombosis acute pulmonary embolism
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 8 May 2006